Who is sponsoring NCT05177926?

NCT05177926 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT05177926?

Interventions in NCT05177926: antiviral prophylaxis with Tenofovir Alafenamide Fumarate.

What condition does NCT05177926 study?

NCT05177926 studies Hepatitis B, Chronic, Mother to Child Transmission.

Is NCT05177926 still recruiting?

NCT05177926 is currently status unknown. Last updated 5 January 2022.

Last reviewed 2022-01-05 · How we verify

NCT05177926

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)

Status unknown Phase 4 Last updated 5 January 2022

What this trial tests

Phase 4 trial testing antiviral prophylaxis with Tenofovir Alafenamide Fumarate in Hepatitis B, Chronic in 330 participants. Status unknown.

Timeline

4 April 2021

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	330
Start date	4 April 2021
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	13 locations across China

Drugs / interventions tested

antiviral prophylaxis with Tenofovir Alafenamide Fumarate — full drug profile →

Conditions studied

Hepatitis B, Chronic — all drugs for Hepatitis B, Chronic →
Mother to Child Transmission — all drugs for Mother to Child Transmission →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 20 to 35, female only, with Hepatitis B, Chronic or Mother to Child Transmission. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of Tenofovir alafenamide (TAF) for prevention of mother-to-child transmission of hepatitis B virus among pregnant women with high level HBV DNA.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Role of pharmacogenetics and tacrolimus dosing in liver transplantation.
Fung J. · · 2023 · cited 5× · PMID 36284080 · DOI 10.1007/s12072-022-10437-1

Verify or expand the search:

Other recruiting trials for Hepatitis B, Chronic

Currently open trials in the same condition.

NCT07370207 — Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region · Phase 2 · recruiting
NCT06550622 — Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion · recruiting
NCT06550128 — Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). · Phase 2 · active not recruiting
NCT06525909 — A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B · recruiting
NCT05937178 — Real-world Study Optimizing Nucleotide-analogues · recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05177926 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 5 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05177926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing